SC
SCPS.US Scopus Biopharma Inc
- Market cap
- USD 25.3K
- P/E
- -
- P/B
- 2.42x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is SCPS.US undervalued?
Graham numberThe Graham number of Scopus Biopharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Scopus Biopharma Inc fundamental analysis
No fundamental analysis for Scopus Biopharma Inc yet.
Scopus Biopharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Scopus Biopharma Inc
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifun…
Full company profileScopus Biopharma Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Scopus Biopharma Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | - | -686K | -2.69M | -10.2M | -27.6M | -11.7M | -9.53M |
| EBITDA | - | - | -2.69M | -10.2M | -27.6M | -11.7M | -9.53M |
| Net Income | - | -686K | -2.69M | -11.6M | -25.5M | -11.6M | -8.69M |
| EPS | - | -0.05 | -0.18 | -0.87 | -1.48 | -0.55 | -0.21 |
| Balance Sheet | |||||||
| Total Assets | 213K | 133K | 772K | 1.97M | 8.19M | 392K | 498K |
| Total Liabilities | 111K | 138K | 855K | 3.81M | 4.17M | 7.45M | 11.0M |
| Shareholders' Equity | 102K | -5.33K | -82.9K | -1.83M | 4.02M | -7.06M | -9.45M |
| Cash & Short-term Investments | 158K | 1.66K | 36.7K | 1.83M | 7.94M | 125K | 362K |
| Total Debt | - | - | - | 2.28M | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -228K | -747K | -2.12M | -2.53M | -11.4M | -8.13M | -2.86M |
| Capital Expenditure | 4.25K | 4.25K | 4.25K | 2.00K | 2.00K | 1.55K | 3.10M |
| Free Cash Flow | - | -747K | -2.12M | -2.53M | -11.4M | -8.13M | -5.96M |
| Ratios | |||||||
| ROE | - | - | - | - | -634.7% | - | - |
| ROA | - | -517.2% | -348.6% | -586.0% | -311.4% | -2,959.7% | -1,747.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Scopus Biopharma Inc dividends
Scopus Biopharma Inc has not paid dividends in the last 6 fiscal years.
Who owns Scopus Biopharma Inc
Top institutions holding SCPS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| M&R Capital Management Inc | 0.00 | 0.00% | -100.00% | Mar 2023 |
| State Street Corporation | 0.00 | 0.00% | -100.00% | Dec 2022 |
| Renaissance Technologies Corp | 0.00 | 0.00% | -100.00% | Dec 2022 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Dec 2022 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Dec 2022 |
| JPMorgan Chase & Co | 0.00 | 0.00% | -100.00% | Dec 2022 |
| Northern Trust Corp | 0.00 | 0.00% | -100.00% | Dec 2022 |
| First Manhattan Co. LLC | 0.00 | 0.00% | -100.00% | Dec 2022 |
| Compagnie Lombard, Odier SCA | 0.00 | 0.00% | -100.00% | Dec 2022 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Dec 2022 |
| HRT FINANCIAL LLC | 0.00 | 0.00% | -100.00% | Dec 2022 |
| Y-Intercept (Hong Kong) Ltd | 0.00 | 0.00% | -100.00% | Dec 2022 |
Scopus Biopharma Inc company profile
- Company name
- Scopus Biopharma Inc
- Ticker
- SCPS.US
- Exchange
- USA Stocks
- Listed since
- Dec 16, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Fiscal year end
- December
- Address
- 420 Lexington Avenue, New York, NY, United States, 10170
- Phone
- 212 479 2513
- Website
- scopusbiopharma.com
About Scopus Biopharma Inc
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. Scopus BioPharma Inc. was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is based in New York, New York.
Scopus Biopharma Inc management
3- Mr. Ira Scott GreenspanSenior Advisor & Director · born 1959
- Mr. Robert J. GibsonVice Chairman, Secretary & Treasurer
- Dr. Alan D. Horsager Ph.D.President?of?Immuno-Oncology and President & CEO of Duet BioTherapeutics · born 1974